Kenneth Olivier
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$6.1MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $6.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 1, 2026 | NIH | SBIR Phase II Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | $990K | Boston Immune Technologies And Therapeutics Inc. |
| Feb 13, 2025 | NIH | SBIR Phase II Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | $927K | Boston Immune Technologies And Therapeutics Inc. |
| Nov 22, 2023 | NIH | SBIR Phase II Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | $777K | Boston Immune Technologies And Therapeutics Inc. |
| Aug 21, 2023 | NIH | SBIR Phase I Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | $298K | Boston Immune Technologies And Therapeutics Inc. |
| Aug 21, 2023 | NIH | SBIR Phase II Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | $298K | Boston Immune Technologies And Therapeutics Inc. |
| May 1, 2023 | NIH | SBIR Phase II Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | $1.2M | Boston Immune Technologies And Therapeutics Inc. |
| Apr 25, 2023 | NIH | SBIR Phase II Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | $1.2M | Boston Immune Technologies And Therapeutics Inc. |
| Aug 31, 2021 | NIH | SBIR Phase II Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | $398K | Boston Immune Technologies And Therapeutics Inc. |
Peer ranks
Federal funding#177
Awards as PI#190
Patents#273
Companies
- Boston Immune Technologies And Therapeutics Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.